Robotic Nanoprobe Enables Precise Extraction of a Single Mitochondrion From a Living Cell

Why It Matters

Label‑free mitochondrial sampling removes phototoxic artifacts, enabling more accurate disease modeling and potential organelle‑based therapies.

Key Takeaways

• Robotic nanoprobe extracts single mitochondria label‑free
• Integrated sensor‑actuator tip detects ROS/RNS signals
• Dielectrophoretic nanotweezers capture organelle within 100 nm
• Extracted mitochondria remain functional after transplantation
• Platform adaptable to other organelles and assays

Pulse Analysis

The ability to study mitochondria inside living cells has been hampered by reliance on fluorescent tags, which can perturb cellular metabolism and introduce phototoxicity. The new robotic nanoprobe sidesteps these limitations by using electrochemical cues—specifically transient bursts of reactive oxygen and nitrogen species—to locate individual organelles. This label‑free approach preserves the native biochemical environment, enabling researchers to capture mitochondria without the bleaching, heat, or chemical interference that traditional microscopy imposes. Consequently, experiments that require downstream genomic or proteomic profiling can proceed with minimal sample alteration, opening new avenues for single‑cell omics.

The probe’s tip combines two nanoelectrodes for real‑time ROS/RNS detection with a pair of dielectrophoretic nanotweezers that generate a localized electric field. When the sensor registers a signal above a calibrated threshold, the actuator engages, pulling the target mitochondrion within roughly one hundred nanometers of the tip. An automated robotic platform orchestrates each step—cell surface identification, membrane penetration, signal monitoring, organelle capture, and safe retraction—ensuring repeatable, low‑invasion procedures. This integration eliminates manual micromanipulation and standardizes intracellular microsurgery across laboratories. The system records every maneuver, providing a digital log for quality control and reproducibility.

Beyond basic research, the technology promises clinical relevance by enabling functional mitochondrial transplantation and precise organelle profiling in disease models such as neurodegeneration and metabolic syndrome. Because the sensing principle relies on metabolic signatures, the platform can be retuned to target lysosomes, peroxisomes, or even pathogenic bacteria, making it a versatile tool for cellular therapeutics and drug screening. As automation lowers the skill barrier, biotech firms may adopt the system for high‑throughput single‑cell assays, accelerating discovery pipelines and potentially informing personalized medicine strategies.